Partial Cellular Reprogramming — Cost Per Dose Economics

Scope and method

This note is a technology economics deep-dive on partial cellular reprogramming, defined here as transient, non-complete expression of Yamanaka reprogramming factors — OCT4, SOX2, KLF4, optionally c-MYC — to partially reset the epigenome without erasing cell identity. The analytical task is to estimate or bound cost per dose.

At access date 2026-05-07, there is no approved commercial partial-reprogramming therapeutic, no disclosed commercial price list, and no public-company product-level COGS for this modality. Therefore, this note treats “cost per dose” as a pre-market engineering-economics problem, not a market quote. It does not fabricate a commercial price.

Source-tier rules applied:

• Tier 1 for technical/IP/performance claims: granted patents, peer-reviewed papers, regulator/standards documents.
• Tier 2 for adoption/company context: company technical pages and self-reported filings.
• No SEO content farms, anonymous benchmark sites, or AI-generated summaries.

Every load-bearing technical claim is labeled with source identifiers and dates. Figures that could not be verified are written as needs primary source validation.

Technical claims and tiered evidence

1. Reprogramming factor identity

The canonical factor set for cellular reprogramming was established by Takahashi and Yamanaka in 2006: OCT3/4, SOX2, KLF4, and c-MYC (OSKM) \Takahashi & Yamanaka 2006, _Cell_, DOI 10.1016/j.cell.2006.07.024, published 2006-08-25, accessed 2026-05-07, [doi.org . That paper is peer-reviewed/Tier 1.

A later independent line of work removed c-MYC to reduce tumorigenicity, using OCT4, SOX2, KLF4 (OSK) \Lu et al. 2020, _Nature_, DOI 10.1038/s41586-020-2975-4, published 2020-12-02, accessed 2026-05-07, [doi.org .

Cross-verification: The factor identity is consistent across Takahashi/Yamanaka 2006, Ocampo 2016, and Lu 2020; multiple institutions and journal lineages support the OSK/OSKM claim.

2. Partial reprogramming in vivo — feasibility evidence

In vivo partial reprogramming is demonstrated in peer-reviewed mouse studies:

• Ocampo et al. 2016, _Cell_, DOI 10.1016/j.cell.2016.11.052, published 2016-12-15, accessed 2026-05-07, doi.org — cyclic partial OSKM induction ameliorated age-associated hallmarks and extended lifespan in a progeria mouse model.
• Lu et al. 2020, _Nature_, DOI 10.1038/s41586-020-2975-4, published 2020-12-02, accessed 2026-05-07, doi.org — OSK expression restored youthful epigenetic information and vision after optic nerve injury in mice.

These are two independent institutions (Salk Institute for Ocampo 2016; Harvard Medical School for Lu 2020), so the load-bearing claim that partial reprogramming can produce beneficial effects in living mammals is cross-verified, not single-source.

3. mRNA delivery route

Because an mRNA-based route is central to cost-per-dose economics, one peer-reviewed paper is relevant:

• Warren et al. 2010, _Cell Stem Cell_, DOI 10.1016/j.stem.2010.08.012, published 2010-11-05, accessed 2026-05-07, doi.org — demonstrated that synthetic modified mRNA can deliver reprogramming factors and generate iPSCs without viral integration.

This supports the technical feasibility of mRNA-mediated reprogramming factor expression. However, for the specific claim “mRNA can be used as a commercial partial-reprogramming dose,” the peer-reviewed lineage is narrow; Turn Biotechnologies’ company technical page also self-reports an mRNA-based ERA platform, but that is Tier 2/self-reported and not independent peer-reviewed proof:

• Turn Biotechnologies, “ERA Platform,” company technical page, accessed 2026-05-07, turn.bio

Therefore, the mRNA route for partial reprogramming is tagged [SINGLE-SOURCE] for commercial translation: Warren 2010 is peer-reviewed, and Turn Bio is company self-report, not an independent second institution.

What the granted patent actually does — and does not do

The strongest verified granted patent in this space is:

• US 8,058,065 B2, “Nuclear reprogramming factor,” granted 2011-11-15, assignee Kyoto University, Google Patents, accessed 2026-05-07, patents.google.com

Important distinctions:

1. It is a granted patent, not an application. That matters for moat analysis: a granted patent has recorded claims; an application does not.
2. The patent is upstream, foundational IP for reprogramming factor use, not a specific partial-reprogramming dosing protocol.
3. The patent does not prove clinical performance, safety, dose economics, or manufacturing cost. It is legal record, not biological proof.
4. Company-specific granted patents from private partial-reprogramming developers were not verified in this note; any asserted Turn Bio/Life Biosciences/Altos patent numbers should be treated as needs primary source validation until retrieved.

Patent-family note: the international counterpart WO 2007/069666 A1 is an application, not a grant, and is not used here as moat evidence.

Unit economics / business model

Who monetizes

There are four potential monetization layers:

1. Developer/therapeutic licensor — private companies such as Turn Biotechnologies, Life Biosciences, and Altos Labs aim to sell, license, or partner reprogramming-based therapeutics. Turn Bio self-reports an mRNA-based ERA platform \Turn Bio platform page, accessed 2026-05-07, [turn.bio . Life Biosciences likewise describes partial-reprogramming programs \Life Biosciences, corporate site, accessed 2026-05-07, [lifebiosciences.com .

1. Tool/consumables suppliers — public companies such as Thermo Fisher Scientific sell reprogramming kits, GMP reagents, and delivery systems \Thermo Fisher Scientific, induced pluripotent stem cell reprogramming product page, accessed 2026-05-07, [thermofisher.com . This layer captures value regardless of which developer wins.

1. IP holder/licensor — Kyoto University and its commercialization arm hold foundational patents such as US 8,058,065 B2 \US 8,058,065 B2, granted 2011-11-15, accessed 2026-05-07, [patents.google.com .

1. CDMO/manufacturing layer — GMP mRNA, LNP, and AAV manufacturing. This layer is implied by the delivery routes, but no public CDMO filing specifically discloses “partial cellular reprogramming” revenue; that is a data gap, not evidence of absence.

Monetization mechanism

The most likely unit-economics models are:

• In vivo one-time or repeat injection: resembles mRNA or AAV gene therapy; value is captured via a drug price per dose, with COGS driven by nucleic acid/LNP/vector manufacturing and QC.
• Ex vivo autologous cell therapy: remove cells, partially reprogram in culture, re-infuse; value is captured via a procedure-like or drug-like price per patient, with COGS driven by cell-manufacturing labor, GMP facility overhead, viral/non-viral reprogramming reagents, and release testing.
• Tool revenue: upstream suppliers monetize kits/reagents today; this is the only currently observable revenue layer.

Margin logic

No disclosed product-level margin exists for partial reprogramming. The mRNA vaccination scale-up shows that high-volume mRNA/LNP manufacturing can support high gross margins, but that is an analogue, not a partial-reprogramming data point. For this note, the quantitative cost model below explicitly treats all input prices as assumed and flags needs primary source validation.

Who captures the value

• If the therapeutic works, developers capture the largest share, less IP royalties and manufacturing costs.
• If it is a tools-and-reagents race, Thermo Fisher, Bio-Techne, and CDMOs capture value as picks-and-shovels.
• If the upstream Kyoto University patent family is enforceable and relevant, the IP holder captures a royalty slice.
• No public company currently discloses partial-reprogramming revenue, so the public-equity value capture is not yet quantified.

Worked quantitative calculation

The calculation below is a bottom-up engineering estimate for an mRNA/LNP-based transient partial-reprogramming dose. It is not a commercial price, and the input values are assumptions unless a primary source is cited.

Formula

\[

COGS_{dose} = (m \times c_{mRNA}) + c_{LNP} + c_{QC}

\]

Where:

• \(m\) = mRNA mass per dose (mg)
• \(c_{mRNA}\) = GMP synthetic mRNA cost per mg (USD)
• \(c_{LNP}\) = lipid/cholesterol/formulation raw material cost per dose (USD)
• \(c_{QC}\) = fill-finish, sterility, and release QC cost per dose (USD)

Base-case inputs

Base-case result

\[

(1 \times 100) + 50 + 75 = \$225 \text{ per dose}

\]

Sensitivity

If the delivery route changes to AAV, the per-dose cost structure changes substantially; a reasonable engineering assumption is that AAV vector manufacturing and QC would put COGS in the $5,000–$50,000 per dose range, but this range is assumed and must be labeled needs primary source validation.

What is excluded

The $225 modeled COGS excludes:

• R&D amortization;
• regulatory filing and clinical trial costs;
• IP royalties, including any Kyoto University/OSKM-family royalty;
• sales, distribution, and hospital administration;
• profit margin.

Therefore, a commercial price would be meaningfully higher than modeled COGS.

Parameter table

Contradictions and source-bound limits

Marketing versus preclinical evidence

Turn Bio’s company page describes an mRNA-based ERA platform aimed at “rejuvenation” \Turn Bio platform page, accessed 2026-05-07, [turn.bio . But peer-reviewed animal work shows that continuous or excessive OSKM expression can cause teratomas and loss of cell identity; partial reprogramming efficacy depends on cyclic, limited expression \Ocampo 2016, DOI 10.1016/j.cell.2016.11.052, published 2016-12-15, accessed 2026-05-07, [doi.org . The company page does not disclose a quantitative dosing window or human safety data. This is a marketing/self-report vs. preclinical evidence gap.

Patent strength vs. performance

US 8,058,065 B2 is real, granted, and foundational \US 8,058,065 B2, granted 2011-11-15, [patents.google.com . But a granted patent is not proof that partial reprogramming is safe, effective, or manufacturable at a given cost. Investors should not treat patent existence as clinical or commercial validation.

Public-filing gap

This note did not locate any public-company SEC filing that discloses a cost per dose or revenue line for partial cellular reprogramming. The primary developers are private companies; public tickers identified below are upstream/adjacent. Therefore, the requested “cost per dose economics” cannot yet be sourced from a 10-K or S-1. This is an absence of confirming disclosure, not a refutation.

Disconfirming Evidence

The thesis that partial cellular reprogramming can become a viable commercial dose would be weakened or falsified by:

1. Teratoma or identity-loss events in any IND-enabling or clinical partial-reprogramming study; the peer-reviewed record already shows that continuous OSKM expression creates this risk \[Ocampo 2016, DOI 10.1016/j.cell.2016.11.052\].
2. Failure to show human efficacy in clinical endpoints such as vision, frailty, organ function, or disease modification; the current evidence is almost entirely mouse/preclinical \[Lu 2020, DOI 10.1038/s41586-020-2975-4\].
3. Failure to reduce manufacturing cost below the modeled ranges — if GMP mRNA, LNP, or AAV costs cannot fall to a level that supports repeat dosing, the unit economics break.
4. No public-company disclosure of revenue or material investment in partial reprogramming over time; if the upstream public tickers do not break out or reference this modality in future filings, the commercial ecosystem is thinner than the private-company narrative suggests.
5. Patent-licensing blockade — if the Kyoto University/OSKM patent estate or other granted patents impose royalties so high that developers cannot price below durable cost, the business model fails despite technical feasibility.
6. Delivery failure — if no system can safely, repeatedly, and selectively deliver OSK/OSKM to target human tissues, dose economics are irrelevant.